What additional data are needed to determine the full scope of the benefit of nonstatin drugs?
More randomized controlled trials (RCTs) are needed to determine the full scope of the benefit of nonstatin drugs, including data on greater reductions of LDL-C and reductions in risk of ASCVD. Additionally, data on other nonstatin drugs as add-on therapies to statin therapies are needed.